Immobilized transferrin Fe3O4@SiO2 nanoparticle with high doxorubicin loading for dual-targeted tumor drug delivery

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4631-4639

  Ding, Wence ^a   Guo, Lin ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Doxorubicin; Nanoparticle; Targeted tumor; Transferrin

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; ACID ANHYDRIDE; DOXORUBICIN; IRON OXIDE SILICON DIOXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; N HYDROXYSUCCINIMIDE; N PHTHALOYL GLUTAMIC ACID ANHYDRIDE; POLYGLUTAMIC ACID; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; IMMOBILIZED PROTEIN; MAGNETITE NANOPARTICLE; NANOPARTICLE; SILICON DIOXIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; PH; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; FE3O4@SIO2; HELA CELL LINE; K562 CELL LINE; TARGETED TUMOR;

DOXORUBICIN; FE3O4@SIO2; NANOPARTICLE; TARGETED TUMOR; TRANSFERRIN;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; HELA CELLS; HUMANS; IMMOBILIZED PROTEINS; K562 CELLS; MAGNETITE NANOPARTICLES; SILICON DIOXIDE; TRANSFERRIN;

EID: 84888867215     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51745     Document Type: Article

References (35)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2): 185-229.
2. Pollakis G, Goormaghtigh E, Ruysschaert JM. Role of the quinine structure in the mitochondrial damage induced by antitumor anthracyclines. Comparison of adriamycin and 5-iminodaunorubicin. FEBS Lett. 1983;155(2): 267-272.
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13): 900-905.
4. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997;11(12): 931-936.
5. Kong SD, Zhang WZ, Lee JH, et al. Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett. 2010;10: 5088-5092.
6. Olariu CI, Yiu HHP, Bouffier L, et al. Multifunctional Fe3O4 nanoparticles for targeted bi-modal imaging of pancreatic cancer. J Mater Chem. 2011;21: 12650-12659.
7. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano today. 2007;2(3): 22-32.
8. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60(23): 6641-6648.
9. Babincova M, Altanerova V, Altaner C, Cicmanec P, Babinec P. In vivo heating of magnetic nanoparticles in alternating magnetic field. Med Phys. 2004;31(8): 2219-2221.
10. Brulé S, Levy M, Wilhelm C, et al. Doxorubicin release triggered by alginate embedded magnetic nanoheaters: a combined therapy. Adv Mater. 2011;23(6): 787-790.
11. Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6(9): 594-602.
12. Gaihre B, Khilb MS, Lee DR, Kim HY. Gelatin-coated magnetic iron oxide nanoparticles as carrier system: drug loading and in vitro drug release study. Int J Pharm. 2009;365(1-2): 180-189.
13. Yu JM, Xie X, Zheng M, et al. Fabrication and characterization of nuclear localization signal-conjugated glycol chitosan micelles for improving the nuclear delivery of doxorubicin. Int J Nanomedicine. 2012;7: 5079-5090.
14. El-Gamel NE, Wortmann L, Arroub K, Mathur S. SiO2@Fe2O3 core-shell nanoparticles for covalent immobilization and release of sparfloxacin drug. Chem Commun (Camb). 2011;47(6): 10076-10078.
15. Allen TM, Cullis PR. Drug delivery systems: entering the nainstream. Science. 2004;303(5665): 1818-1822.
16. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12): 751-760.
17. Pearce TR, Shroff K, Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater. 2012;24(28): 3803-3822, 3710.
18. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8(4): 1172-1181.
19. Yu MK, Park J, Jeong YY, Moon WK, Jon S. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology. 2010;21(41): 415102.
20. Toublan FJJ, Boppart S, Suslick KS. Tumor targeting by surface-modified protein microspheres. J Am Chem Soc. 2006;128(11): 3472-3473.
21. Indira Chandran V, Matesic L, Locke JM, Skropeta D, Ranson M, Vine KL. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett. 2012;316(2): 151-156.
22. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121(2): 144-158.
23. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121(2);159-176.
24. Peng JL, Wu S, Zhao XP, et al. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem Biophys Res Commun. 2007;354(4): 864-871.
25. 3 particles. Chem Mater. 1996;8(9): 2209-2211.
26. Liu X, Ma Z, Xing J, Liu H. Preparation and characterization of amino-silane modified superparamagnetic silica nanospheres. J Magn Magn Mater. 2004;270(1-2): 1-6.
27. Guo L, Huang J, Zhang X, Li Y, Zheng L. Bacterial magnetic nanoparticle as a drug carrier. J Mater Chem. 2008;18: 5993-5997.
28. Bliss C. The calculation of the dose-mortality curve. Ann Appl Biol. 1935;22: 134-167.
29. Ciofani G, Del Turco S, Genchi GG, D'Alessandro D, Basta G, Mattoli V. Transferrin-conjugated boron nitride nanotubes: protein grafting, characterization, and interaction with human endothelial cells. Int J Pharm. 2012;436(1-2): 444-453.
30. Du W, Xu Z, Nystrom AM, Zhang K, Leonard JR, Wooley KL. 19F-and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery. Bioconjug Chem. 2008;19(12): 2492-2498.
31. Guo S, Li D, Zhang L, Li J, Wang E. Monodisperse mesoporous superparamagnetic single-crystal magnetite nanoparticles for drug delivery. Biomaterials. 2009;30(1): 1881-1889.
32. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release. 2007;118(1): 7-17.
33. Meza Mary. Chapter 22: Application of magnetic particles in immunoassays. In: Hafeli U, Schutt W, Zborowski M, editors. Scientific and Clinical Applications of Magnetic Carriers. New York: Plenum; 1997: 303-310.
34. Xu X, Deng C, Gao M, Yu W, Yang P, Zhang X. Synthesis of magnetic microspheres with immobilized metal ions for enrichment and direct determination of phosphopeptides by matrix-assisted laser desorption ionization mass spectrometry. Adv Mater. 2006;18(24): 3289-3293.
35. Sahu SK, Maiti S, Pramanik A, Ghosh SK, Pramanik P. Controlling the thickness of polymeric shell on magnetic nanoparticles loaded with doxorubicin for targeted delivery and MRI contrast agent. Carbohydr Polym. 2012;87(4): 2593-2604.